There has been some controversy on the role of taxanes in combination with platinum for the treatment of ovarian cancer. In the current report, patients who relapsed after a disease-free interval of 6 months or more were randomized in 2 large, multicenter trials conducted in Europe to receive either platinum (or typical platinum-based regimens) or paclitaxel plus platinum.